Navigation Links
Convergence Pharmaceuticals Initiates Phase I Multiple Ascending Dose Study for CNV2197944
Date:11/21/2011

to support the clinical development of CNV2197944 have also been completed, which suggest an excellent margin of safety and tolerability.

The need for new drug treatments for chronic pain

The Pain therapeutic area encompasses any disease where pain is a major symptom. The unmet medical need for patients in pain is enormous, with the greatest need being for a more effective therapy that is well tolerated and safe over a long period of time. Within the pain marketplace, current pain treatments are unsatisfactory; overall efficacy is poor (typically 1-2 point reductions on a 10 point scale) and satisfactory to less than 50% of patients. Whilst treatments, such as opioids and non-steroidal anti-inflammatory drugs, are available on the market, many patients obtain little or no relief from these existing analgesics. Often such drugs are associated with adverse events, side effects and addiction concerns, leading to the observation in a recent report by the US Institute of Medicine that a "cultural transformation" is necessary to better prevent, assess, treat, and understand pain of all types.[1]

This highlights the importance of Convergence Pharmaceuticals' goals to develop novel, efficacious analgesics with improved pharmacology and safety profiles.

About chronic pain

Currently, more than 1.5 billion people worldwide suffer from chronic pain of varying degrees, with an estimated 116 million American adults affected by chronic pain - more than heart disease, cancer and diabetes combined.[2] Among all types of chronic pain, neuropathic pain stands out with approximately 3-4.5% of the global population affected, with incidence rate increasing in line with increased age of the population. With the unmet clinical need so high, the demand for better pain management therapies, addressing acute and chronic pain, is on the rise.

According to recent research the global pain management market is to reach US
'/>"/>

SOURCE Convergence Pharmaceuticals Ltd
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. Convergence Pharmaceuticals Announces Start of Phase II Study for its Selective Nav 1.7 blocker CNV1014802
2. Nano-Bio-Info-Cogno Revolutions to be Explored at Convergence08 Unconference - Forecaster Paul Saffo to Keynote
3. Keryx Biopharmaceuticals, Inc. Announces Upcoming Poster Presentations of Zerenex™ (Ferric Citrate) at the Upcoming American Society of Nephrology Kidney Week 2011 Annual Meeting
4. Access Pharmaceuticals Signs Agreement for CobaCyte® and CobOral® in RNAi Therapeutic Delivery
5. Radient Pharmaceuticals Announces Proxy Resolutions Approved at Special Meeting of Stockholders
6. Cumberland Pharmaceuticals Reports Third Quarter 2011 Financial Results
7. Optimer Pharmaceuticals Reports Third Quarter 2011 Financial Results
8. Cadence Pharmaceuticals CEO Ted Schroeder to Present at the Credit Suisse Healthcare Conference on November 9, 2011
9. Optimer Pharmaceuticals to Present at 20th Annual Credit Suisse Healthcare Conference
10. Auxilium Pharmaceuticals, Inc. Announces Third Quarter 2011 Financial Results and Recent Operational Highlights
11. Optimer Pharmaceuticals to Host Conference Call and Webcast to Discuss Third Quarter 2011 Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/22/2015)... 22, 2015 Pipette.com has added the ... their comprehensive portfolio of Eppendorf products. , The Eppendorf ... a Centrifuge 5424/5424 R and receive the following:, ... Research plus or Eppendorf Reference 2 , ...
(Date:1/22/2015)... Denville, NJ (PRWEB) January 22, 2015 ... shearing technologies such as the Bioruptor® and complete ... semi-automation system for chromatin immunoprecipitation, alleviating the need ... reagents and controls needed for ChIP of histones ...
(Date:1/22/2015)... N.J. , Jan. 22, 2015  Derma Sciences, ... regeneration company focused on advanced wound care, announces ... placental tissues, have been added to the Premier, ... increases the opportunity for the AMNIOEXCEL® and AMNIOMATRIX® ...
(Date:12/24/2014)... BioLife Solutions , Inc. (NASDAQ: BLFS ), a ... hypothermic storage and cryopreservation freeze media and ... ("BioLife" or the "Company"), today announced that it will hold ... (the "Annual Meeting"). Because the expected date for ...
Breaking Biology Technology:Eppendorf Announces Promotional Bundle Which Includes: Eppendorf Centrifuge 5424, 3-Pack of Pipettes, and Tips - Available Now at Pipette.com 2Diagenode Launches Unique Semi-Automated Solution for Chromatin Immunoprecipitation 2Derma Sciences Expands Access of its AMNIOTIC TISSUE Product Line with New Premier, Inc. Agreement 2Derma Sciences Expands Access of its AMNIOTIC TISSUE Product Line with New Premier, Inc. Agreement 3Derma Sciences Expands Access of its AMNIOTIC TISSUE Product Line with New Premier, Inc. Agreement 4Derma Sciences Expands Access of its AMNIOTIC TISSUE Product Line with New Premier, Inc. Agreement 5BioLife Solutions Sets Date for Annual Meeting of Stockholders 2
... -- Bruker AXS Inc. on Thursday announced the promotions ... to executive vice presidents, responsible for leading all aspects ... the Madison headquarters of Bruker AXS, now leads the ... as chief technology officer heads global R&D. , ,Burgaezy, ...
... describes today's go-it-alone economic climate than the word "entrepreneur." ... appealing to those who would strike out on their ... large and small along with colleges and universities and ... to help them in their quests to be successful ...
... CHICAGO -Last week, we talked about the size and ... key market segments. This week's column will focus on the ... , ,Before we comment on some trends from this ... absent here is the major part of the diagnostics business ...
Cached Biology Technology:Beware -- Use of the word 'entrepreneur' can put you in a legal mess 2Beware -- Use of the word 'entrepreneur' can put you in a legal mess 3Beware -- Use of the word 'entrepreneur' can put you in a legal mess 4Beware -- Use of the word 'entrepreneur' can put you in a legal mess 5Midwest plays key role in developing new medical device companies 2Midwest plays key role in developing new medical device companies 3
(Date:12/22/2014)... 22, 2014  NXT-ID, Inc. (NASDAQ: NXTD and ... on the growing mobile commerce market, announces it has retained ... for the 2015 International CES debut of the Wocket™ biometric ... be at the NXT-ID booth January 6th and 7 th ...
(Date:12/19/2014)... , Dec. 18, 2014  23andMe, Inc., the leading personal genetics ... fine-scale differences in genetic ancestry of individuals from across ... first arrived more than four hundred years ago, ... place for peoples from different continents. This study illuminates how ...
(Date:12/17/2014)... 16, 2014 Valencell, a leader in performance biometric ... to industry leaders such as Intel, Jabra, Atlas, and ... wearable products. These products will be showcased at CES ... Vegas . "Our partners choose ...
Breaking Biology News(10 mins):NXT-ID Hires Master Pickpocket and Security Consultant Apollo Robbins for Wocket Smart Wallet CES 2015 Debut 2NXT-ID Hires Master Pickpocket and Security Consultant Apollo Robbins for Wocket Smart Wallet CES 2015 Debut 3NXT-ID Hires Master Pickpocket and Security Consultant Apollo Robbins for Wocket Smart Wallet CES 2015 Debut 423andMe Study Sketches Genetic Portrait of the United States 223andMe Study Sketches Genetic Portrait of the United States 323andMe Study Sketches Genetic Portrait of the United States 4Valencell PerformTek Biometrics Power the Most Accurate Wearables at CES 2015 2
... For 25 years, researchers have tried and failed to develop ... of engineered "super antibodies" to fend off the virus ... have proved impossible to produce in people. Now, in research ... scientists at The Rockefeller University have laid out a new ...
... of iron homeostasis is a common feature of prion ... new study by Dr. Neena Singh and colleagues at ... from Creighton University. These findings, published March 13 in ... insight into the mechanism of neurotoxicity in prion disorders, ...
... at Kansas State,University, with collaboration from Epitopix LLC, ... E. coli O157 in beef cattle. ... on the post-harvest food safety,aspect, whether it,s ... of,K-State,s College of Veterinary Medicine. Thomson is the ...
Cached Biology News:A natural approach for HIV vaccine 2A natural approach for HIV vaccine 3Iron is involved in prion disease-associated neuronal demise 2K-State researchers help Epitopix license the United States' first E. coli O157 vaccine for cattle 2
Activating Agents, 7-azabenzotriazol-1-yloxy-tris-(pyrrolidino)phosphonium hexafluorophosphate...
... Clone/PAD: ZMD.283. Immunogen: Fusion ... Specificity: Specific for ASIP/PAR-3 (atypical PKC ... This antigen is not related to ... Reactivity: Human Dog Xenopus (positive controls: ...
...
Request Info...
Biology Products: